Isosorbide Dinitrate
drugOn this page
Also known as AngitakC01DA08CarvasinCedocardCedocard retCedocard-10Cedocard-20Cedocard-40Cedocard-5DilatrateDilatrate-srDiluted isosorbide dinitrateDiluted isosorbide dinitrate rsDiluted-isosorbide dinitrateDinitrate d'isosorbideDinitrato de isosorbidaImtackIso mackIsocardIsoket 10
Summary
Isosorbide Dinitrate (CHEMBL6622) is an approved small-molecule vasodilator agent (ATC C05AE02); indicated across 9 conditions including cardiovascular disorder and hemorrhoid.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C05AE02 (+2 more)
- Indications: 9 conditions
- Clinical trials: 19
- Chemistry: 236.14 Da · C6H8N2O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6622 |
| Name | Isosorbide Dinitrate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6883 |
| ChEBI | CHEBI:6061 |
| ATC | C05AE02, C01DA08, C01DA58 |
| Molecular formula | C6H8N2O8 |
| Molecular weight | 236.14 |
| InChIKey | MOYKHGMNXAOIAT-JGWLITMVSA-N |
SMILES: C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]
IUPAC name: [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
Pharmacological roles (ChEBI): vasodilator agent, nitric oxide donor.
Also known as: Angitak, C01DA08, Carvasin, Cedocard, Cedocard ret, Cedocard-10, Cedocard-20, Cedocard-40, Cedocard-5, Dilatrate, Dilatrate-sr, Diluted isosorbide dinitrate
Patent coverage: 9,443 distinct patent families (26,819 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Beta-lactamase.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P00811 | 5.25 | Potency | 5623 | nM | CHEMBL_ACT_4642179 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| hemorrhoid | 4 | MONDO:0004872 | EFO:0009552 |
| coronary artery disorder | 4 | MONDO:0005010 | EFO:0001645 |
| myocardial ischemia | 3 | MONDO:0024644 | EFO:1001375 |
| congestive heart failure | 2 | MONDO:0005009 | EFO:0000373 |
| heart failure | 2 | MONDO:0005252 | EFO:0003144 |
| Duchenne muscular dystrophy | 1 | MONDO:0010679 | MONDO:0010679 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 5 |
| Not specified | 5 |
| PHASE3 | 4 |
| PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05276219 | PHASE4 | RECRUITING | Optimized Treatment of Pulmonary Edema or Congestion |
| NCT06218199 | PHASE4 | RECRUITING | Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts |
| NCT01513070 | PHASE4 | COMPLETED | A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis |
| NCT02488642 | PHASE4 | COMPLETED | Medical Management of Late Intrauterine Death. |
| NCT06400784 | PHASE4 | COMPLETED | Hypertensive Heart Failure Treatment in SSA |
| NCT00000478 | PHASE3 | COMPLETED | Asymptomatic Cardiac Ischemia Pilot (ACIP) Study |
| NCT01822808 | PHASE3 | UNKNOWN | Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure |
| NCT02343393 | PHASE3 | UNKNOWN | Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study |
| NCT02789033 | PHASE3 | COMPLETED | Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers |
| NCT00262470 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Treatment of Orthostatic Intolerance |
| NCT01516346 | PHASE2 | COMPLETED | Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction |
| NCT04297241 | PHASE2 | COMPLETED | Nitrate Effect on Exercise Capacitance |
| NCT01478022 | PHASE1 | COMPLETED | To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 |
| NCT01587313 | PHASE1 | COMPLETED | A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers |
| NCT02135315 | Not specified | COMPLETED | Intensive Arterial Pressure Control in Acute Coronary Syndrome |
| NCT02368795 | Not specified | UNKNOWN | Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis |
| NCT02649998 | Not specified | WITHDRAWN | Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF |
| NCT02718521 | Not specified | UNKNOWN | Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN |
| NCT04425993 | Not specified | UNKNOWN | Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).